ITCC in the groove, CBAI busy, LRDC goes south

InsPro Technologies Corp. (OTCBB: ITCC) doubled in price to six cents Monday. Volume for the stock was a light 28,000 shares, compared to a daily average of 35,000. On Friday, the company released financial information for 2010, which included a net loss of $2.5 million or ($0.06) per share in 2010, compared with net loss of $6.3 million, or ($0.14) per share in 2009.

Cord Blood America Inc. (OTCBB: CBAI) shares were flat at 22-100ths of a cent Monday, but those shares were widely traded; 45.2 million in all Monday, compared to a daily average of 48.3 million.

Laredo Oil Inc. (OTCBB: LRDC) took a pasting Monday, losing 54.9% of its muscle to 73 cents. Volume for LRDC was 54,650 shares, nosing out a daily average of 48,502. Austin-based LRDC is an exploration and production company specializing in Enhanced Oil Recovery techniques targeting mature and declining oil fields.

EXTL excels, CBAI shares flow, RPBC in red

ExperTelligence Inc. (OTCBB: EXTL) ballooned in price 1,150% Thursday to close at 25 cents. Volume for the stock was 15,000, short of its average of 25,000.

Cord Blood America Inc. (OTCBB: CBAI) shares flew off the shelves Thursday, at the rate of 53 million, topping its average of 46 million. Share prices ducked back 8.7% to 21-100ths of a cent, only days after joining with BlueCross BlueShield of Tennessee to offer stem cell collection services.

Redpoint Bio Corp. (Pink Sheets: RPBC) lost 46.7% of its price strength Thursday, closing at 3.2 cents, on volumes of 338,130 shares, compared to its usual average of 91,156.

FXPT leaps, CBAI busy, PTS in the pits

Fox Petroleum Inc. (Pink Sheets: FXPT) shot out of the blocks 185.7% higher in price to two cents. Volume for the stock was one million shares, dwarfing an all-day average of 306,739, after signing a letter of intent to with Camelot Oil Energy S.A. to develop and finance oil projects located in Latin America.

Cord Blood America Inc. (OTCBB: CBAI) dealt in a whopping 22.1 million shares early Wednesday morning, about halfway to its all-day average. Share prices were flat, though, at 23-100ths of a cent. The Vegas-based CBAI is an umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally.

PTS Inc. (Pink Sheets: PTSH) took a stumble Wednesday morning, losing 50% of its price strength to one-100th of a cent, on volume of 30,350 shares. Regular daily volume is around 15.9 million.

Cord Blood America (CBAI) volume skyrockets on acquisition news

Cord Blood America, Inc. (OTCBB: CBAI) experienced explosive activity Monday, trading nearly 40 million shares after announcing this morning that the Company has acquired a 50.1 percent controlling interest in Biocordcell Argentina S.A. (BioCells, Inc.), one of South America’s largest stem cell companies. Cord  Blood America primarily focuses on the preservation of umbilical cord blood stem cell  in order to bring the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally.

Commanding a major part of the market in South America, BioCells is headquartered in Argentina with operations in Peru, Colombia, Bolivia, Panama and Puerto Rico, with recent expansion into Uruguay and Paraguay.  Purchase price for the profitable stem cell storage company, the second largest in Argentina, depends on achieving earn out targets for net profit over the next two years.

BioCells, Inc. reported 2009 annual revenues of $1.2 million (US), and operates twelve locations throughout Argentina, serving the nation of 40 million people that historically saves umbilical cord blood stem cells at a rate even higher than in the United States.

Co-founder and Chief Executive Officer of Cord Blood America, Matthew Schissler commented, “We expect revenues from BioCells to be approximately $1.7 million in 2010, with a profit of $150,000 (U.S.) before taxes. With this acquisition in South America, we now own a state-of-the-art large laboratory in Las Vegas, Nevada, a stem cell company in Germany with expansion plans throughout Europe, and we are partners in what could be the world’s largest stem cell storage facility in China.  We are quite proud of the accomplishments of Cord Blood America and we have no intention of slowing our aggressive growth strategy.”

Schissler concluded, “This is an historic day for Cord Blood America, our loyal investors and stakeholders.  We will not rest until we meet our goal of becoming the world’s premier stem cell storage company.”